尿液p75ECD:肌萎缩侧索硬化症的预后、疾病进展与药效生物标志物
研究纳入45名健康对照和54例肌萎缩侧索硬化症(ALS)患者(其中31例纵向采样),评估尿液神经生长因子受体p75胞外域(p75ECD)作为疾病进展与预后标志物。结果显示ALS患者尿液p75ECD高于对照,与修订版ALS功能评分量表(ALSFRS-R)负相关,随疾病进展每月平均升高0.19 ng/mg肌酐,基线水平为独立生存预测因子。
要点
- 尿液p75ECD在ALS患者中升高,检测方法重复性好、稳定性高。
- p75ECD与ALSFRS-R负相关,并随疾病进展每月平均升高0.19 ng/mg肌酐。
- 基线p75ECD、球部起病及起病至基线进展速率均为生存预测因子。
核心结论
- 尿液p75ECD检测稳健,有望作为ALS的预后、疾病进展及潜在药效生物标志物。
- 基线尿液p75ECD可提供预后信息,是目前唯一基于体液的疾病进展生物标志物。
研究设计与样本
- 研究纳入45名健康对照和54例ALS患者,其中31例进行纵向采样。
- 采用酶联免疫分析法测定尿液p75ECD,并验证批内与批间变异系数、昼夜节律影响及室温、4°C和反复冻融下的稳定性。
- 纵向变化用混合模型分析,基线p75ECD的预后价值用生存分析探索。
主要发现
- ALS患者尿液p75ECD为5.6 ± 2.2 ng/mg肌酐,高于对照的3.6 ± 1.4 ng/mg肌酐(p < 0.0001)。
- p75ECD与首次评估时ALSFRS-R相关(r = -0.44,p = 0.008),与全部研究访视的ALSFRS-R相关(r = -0.36,p < 0.0001)。
- p75ECD随疾病进展平均每月升高0.19 ng/mg肌酐(p < 0.0001)。
- 多因素预后分析中,球部起病(HR 3.0,p = 0.0035)、起病至基线疾病进展速率(HR 4.4,p < 0.0001)和基线p75ECD(HR 1.3,p = 0.0004)为生存预测因子。
关键数值与推荐
- ALS患者与对照尿液p75ECD分别为5.6 ± 2.2与3.6 ± 1.4 ng/mg肌酐(p < 0.0001)。
- p75ECD与ALSFRS-R首次评估r = -0.44(p = 0.008),全部访视r = -0.36(p < 0.0001)。
- p75ECD随疾病进展平均每月升高0.19 ng/mg肌酐(p < 0.0001)。
- 生存预测:球部起病HR 3.0(p = 0.0035)、起病至基线进展速率HR 4.4(p < 0.0001)、基线p75ECD HR 1.3(p = 0.0004)。
临床怎么用
- 可考虑检测基线尿液p75ECD辅助ALS预后评估。
- 可用尿液p75ECD纵向监测疾病进展,其与ALSFRS-R变化相关。
- p75ECD检测稳定、无昼夜变异,适合重复采样,但尚需进一步验证后用于药效评价。
局限性
- 样本量较小(54例ALS患者,31例纵向采样),结果需更大队列验证。
- 摘要未报告检测方法的标准化细节及多中心验证情况。
- 药效动力学应用仅为潜在方向,原文未提供干预研究数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate urinary neurotrophin receptor p75 extracellular domain (p75ECD) levels as disease progression and prognostic biomarkers in amyotrophic lateral sclerosis (ALS). METHODS: The population in this study comprised 45 healthy controls and 54 people with ALS, 31 of whom were sampled longitudinally. Urinary p75ECD was measured using an enzyme-linked immunoassay and validation included intra-assay and inter-assay coefficients of variation, effect of circadian rhythm, and stability over time at room temperature, 4°C, and repeated freeze-thaw cycles. Longitudinal changes in urinary p75ECD were examined by mixed model analysis, and the prognostic value of baseline p75ECD was explored by survival analysis. RESULTS: Confirming our previous findings, p75ECD was higher in patients with ALS (5.6 ± 2.2 ng/mg creatinine) compared to controls (3.6 ± 1.4 ng/mg creatinine, p < 0.0001). Assay reproducibility was high, with p75ECD showing stability across repeated freeze-thaw cycles, at room temperature and 4°C for 2 days, and no diurnal variation. Urinary p75ECD correlated with the revised ALS Functional Rating Scale at first evaluation (r = -0.44, p = 0.008) and across all study visits (r = -0.36, p < 0.0001). p75ECD also increased as disease progressed at an average rate of 0.19 ng/mg creatinine per month (p < 0.0001). In multivariate prognostic analysis, bulbar onset (hazard ratio [HR] 3.0, p = 0.0035), rate of disease progression from onset to baseline (HR 4.4, p < 0.0001), and baseline p75ECD (HR 1.3, p = 0.0004) were predictors of survival. CONCLUSIONS: The assay for urinary p75ECD is analytically robust and shows promise as an ALS biomarker with prognostic, disease progression, and potential pharmacodynamic application. Baseline urinary p75ECD provides prognostic information and is currently the only biological fluid-based biomarker of disease progression.
引用
- Shepheard SR, Wuu J, Cardoso M, et al. Urinary p75ECD: A prognostic, disease progression, and pharmacodynamic biomarker in ALS. Neurology. 2017. PMID: 28228570. doi:10.1212/WNL.0000000000003741
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。